List view / Grid view
From richer biomarker content to patient-friendly sampling, first-void urine is emerging as a promising tool in precision health. Here is why scientists are paying attention.
An advocate for genetic medicines and the enormous potential they hold, Leah Sabin at Regeneron Genetic Medicines reveals how passion and curiosity can forge the path to a rewarding career in STEM.
19 February 2025 | By
Discover the transformative potential of iPSC-based therapies in regenerative medicine, alongside their challenges including scalability, safety and targeted delivery.
Grifols' Chronos-PD initiative leverages its extensive plasma repository to identify early biomarkers of Parkinson's disease, advancing early detection and contributing to the development of innovative therapies.
Drug discovery scientists develop and test complex hypotheses using data and expertise, and build workflows to support this. In this third and final article, Dr Raminderpal Singh and Nina Truter summarise the tools used in the scientific workflow – and include key considerations.
How are clinical genomics and AI transforming drug development? Industry experts reveal how these technologies improve target identification, patient stratification, and trial design to drive higher success rates.
CTMC, a joint venture between Resilience + MD Anderson Cancer Center, is transforming cancer treatment with faster, more efficient cell therapy development - learn how they’re doing it.
Study reveals how type 2 diabetes accelerates cognitive decline by damaging white matter in the brain. Sam Hashemi at Prenuvo explains how advanced AI and whole-body MRI technology are opening new possibilities for early intervention.
Posdinemab, being investigated by Johnson & Johnson, has received FDA fast-track status. Hear from Dr Fiona Elwood as she explains how Johnson & Johnson’s precision medicine approach could transform Alzheimer’s treatment.
New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the potential for long-term remission.
A new study suggests that targeting serotonin in the gut, rather than the brain, could lead to antidepressants with fewer side effects.
Explore how FDA’s Project Optimus is reshaping oncology drug dosing strategies, with insights on precision medicine, adaptive trial designs, and the role of CROs in optimising patient outcomes.
Macrocycles outperform traditional therapeutics on several fronts, yet they account for just four percent of FDA-approved drugs. Colleagues Ann E Cleves and Ajay N Jain from Optibrium Ltd explain why we can expect to see this number increase in the coming years.
In part two of the step-by-step scientific workflow for drug discovery series, Dr Raminderpal Singh and Nina Truter describe the functions of the workflow previously outlined and include key considerations.
Find out how Confo Therapeutics is overcoming challenges in GPCR drug development to create next-gen therapies for metabolic diseases.
Learn how the University at Buffalo is pioneering safer, more effective ADC therapies.
